DACHS

The DACHS study is an epidemiological case-control study and patient cohort study on colorectal cancer. DACHS stands for "Colorectal Cancer: Opportunities for Prevention through Screening".
For the DACHS study, a total of 7500 colorectal cancer patients and >8000 randomly selected control persons without colorectal cancer were recruited between 2003 and 2021 in order to subsequently compare them with each other. The control persons correspond to the patients in age and gender and come from the same cities and districts. The patients are followed up for 20 years to see how their disease progresses.
“With the DACHS study, we want to make a significant contribution to enabling even better colorectal cancer screening and colorectal cancer prognosis in the future.”
Michael Hoffmeister, Study PI
Principal Investigators
-
Prof. Dr. Michael Hoffmeister
Interim division head, group leader
-
Prof. Dr. Hermann Brenner
Head of department
Study description

Study population
Patients: first diagnosis of primary colorectal cancer; control persons: frequency-matched by age, gender and city/county of patients and contacted after random selection.
Recruitment/diagnosis period
2003-2021
Study region
Rhine-Neckar-Odenwald area; all >20 clinics in the study region that offering colorectal cancer surgery
Inclusion criteria
Minimum age 30 years (no upper age limit), first residence in the DACHS study region, good knowledge of German, able to conduct an interview
Interview questionnaire
Sociodemographic information, risk factors and preventive factors, medication use, medical history
Medical findings
Endoscopy reports from previous colonoscopies, discharge letters (patients only), pathology report (patients only)
Biosamples
Blood sample, tumor tissue sample (FFPE, patients only)
Before all follow-ups (patients only)
Vital status and address check with the population registers
3-year follow-up
Treating physicians / medical findings: colorectal cancer therapy, comorbidities, recurrence
5-, 10-, 15-, 20-year follow-up
Patient questionnaire + medical findings: risk factors and preventive factors, comorbidities, recurrence, quality of life, long-term and late effects
The DACHS study was or is funded by the following institutions and organizations:
- German Research Foundation (DFG): BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HO 5117/2-2, HE 5998/2-1, HE 5998/2-2, KL 2354/3-1, KL 2354 3-2, RO 2270/8-1, RO 2270/8-2, BR 1704/17-1, BR 1704/17-2
- Federal Ministry of Education and Research (BMBF): 01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER1505B, 01KD2104A
- National Institutes of Health (NIH), USA: U01 CA137088, U01 CA164930
- German Cancer Aid: 70116154
- National Center for Tumor Diseases (NCT), Heidelberg: Interdisciplinary research program
- German Cancer Research Center: Heidelberg Center for Personalized Oncology (HIPO) Program
- Ministry of Science, Research and the Arts, Baden-Württemberg: Funding stream Medicine
The DACHS study is the main study or part of large, national and international research consortia in which colorectal cancer research questions can be investigated even more comprehensively or in significantly larger study populations.
IMPACT 1/2 Consortium: "Improving long-term prognosis and quality of life of patients with colorectal cancer", Heidelberg, 2009-2021.
GECCO Consortium: "Genetics and Epidemiology of Colorectal Cancer Consortium", Seattle (Washington, USA), since 2009.
ISACC Consortium: "International Survival Analysis in Colorectal Cancer Consortium", Seattle (Washington, USA), since 2015.
IMPACT 3 Consortium: "Influence of clinical factors, therapy and lifestyle on long-term and late effects in colorectal cancer survivors", Heidelberg, since 2025.
DACHS Study Center
German Cancer Research Center (DKFZ)
Division of Clinical Epidemiology and Aging Research
Im Neuenheimer Feld 581
69120 Heidelberg
Telephone: 06221-42-1320
Results of the DACHS study
More than 300 scientific articles have been published to date with the data and samples from the DACHS study. This has provided important, practice-relevant findings for colorectal cancer screening and early detection, as well as on the influence of lifestyle factors and genetics.
The investigation of prognostic markers, molecular pathological profiles and other influences such as comorbidities have also led to new findings for clinical practice. The long-term follow-up in the DACHS study can answer questions about quality of life as well as long-term and late effects in colorectal cancer patients with the aim of further improving patient care.
In addition to advanced epidemiological methods, we are increasingly using AI methods to examine the comprehensively characterized patient cohort of the DACHS study as well as the images of the tumor tissue or the highly complex molecular biological data with regard to personalized treatment and prognosis.
Selected publications
Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status
Wankhede D, Halama N, Kloor M, Brenner H, Hoffmeister M
Wankhede D, Halama N, Kloor M, Edelmann D, Brenner H, Hoffmeister M.
Yuan T, Wankhede D, Edelmann D, Kather JN, Tagscherer KE, Roth W, Bewerunge-Hudler M, Brobeil A, Kloor M, Bläker H, Brenner H, Hoffmeister M
Mandic M, Safizadeh F, Niedermaier T, Hoffmeister M, Brenner H
Hoffmeister M, Bläker H, Jansen L, Alwers E, Amitay EL, Carr PR, Kloor M, Herpel E, Roth W, Chang-Claude J, Brenner H
Carr PR, Weigl K, Edelmann D, Jansen L, Chang-Claude J, Brenner H, Hoffmeister M
Boakye D, Walter V, Jansen L, Martens UM, Chang-Claude J, Hoffmeister M, Brenner H
Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, Grabsch HI, Yoshikawa T, Brenner H, Chang-Claude J, Hoffmeister M, Trautwein C, Luedde T
Bläker H, Alwers E, Arnold A, Herpel E, Tagscherer KE, Roth W, Jansen L, Walter V, Kloor M, Chang-Claude J, Brenner H, Hoffmeister M
Carr PR, Weigl K, Jansen L, Walter V, Erben V, Chang-Claude J, Brenner H, Hoffmeister M
Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chang-Claude J, Chanock SJ, Cotterchio M, Duggan D, Figueiredo JC, Fuchs CS, Giovannucci EL, Gong J, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hudson TJ, Jenkins MA, Jiao S, Lindor NM, Lemire M, Le Marchand L, Newcomb PA, Ogino S, Pflugeisen BM, Potter JD, Qu C, Rosse SA, Rudolph A, Schoen RE, Schumacher FR, Seminara D, Slattery ML, Thibodeau SN, Thomas F, Thornquist M, Warnick GS, Zanke BW, Gauderman WJ, Peters U, Hsu L, Chan AT; CCFR; GECCO
Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M
Jiao S, Peters U, Berndt S, Brenner H, Butterbach K, Caan BJ, Carlson CS, Chan AT, Chang-Claude J, Chanock S, Curtis KR, Duggan D, Gong J, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Kolonel LN, Le Marchand L, Potter JD, Rudolph A, Schoen RE, Seminara D, Slattery ML, White E, Hsu L
Brenner H, Chang-Claude J, Rickert A, Seiler CM, Hoffmeister M
Jansen L, Hoffmeister M, Chang-Claude J, Brenner H, Arndt V
Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M
Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M
Brenner H, Chang–Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M